000169665 001__ 169665
000169665 005__ 20240326150822.0
000169665 0247_ $$2doi$$a10.1002/ijc.33725
000169665 0247_ $$2pmid$$apmid:34196970
000169665 0247_ $$2ISSN$$a0020-7136
000169665 0247_ $$2ISSN$$a1097-0215
000169665 0247_ $$2altmetric$$aaltmetric:108531281
000169665 037__ $$aDKFZ-2021-01487
000169665 041__ $$aEnglish
000169665 082__ $$a610
000169665 1001_ $$aPapadimitriou, Nikos$$b0
000169665 245__ $$aCirculating tryptophan metabolites and risk of colon cancer: results from case-control and prospective cohort studies.
000169665 260__ $$aBognor Regis$$bWiley-Liss$$c2021
000169665 3367_ $$2DRIVER$$aarticle
000169665 3367_ $$2DataCite$$aOutput Types/Journal article
000169665 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1711462070_22852
000169665 3367_ $$2BibTeX$$aARTICLE
000169665 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000169665 3367_ $$00$$2EndNote$$aJournal Article
000169665 500__ $$a2021 Nov 1;149(9):1659-1669
000169665 520__ $$aDysregulation of tryptophan metabolism has been linked to colorectal tumorigenesis, however, epidemiological studies investigating tryptophan metabolites in relation to colorectal cancer risk are limited. We studied associations of plasma tryptophan, serotonin, and kynurenine with colon cancer risk in two studies with cancer patients and controls, and in one prospective cohort: ColoCare Study (110 patients/153 controls), the Colorectal Cancer Study of Austria (CORSA; 46 patients/390 controls), and the European Prospective Investigation into Cancer and Nutrition (EPIC; 456 matched case-control pairs). Logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) for colon cancer risk. Tryptophan was inversely associated with colon cancer risk in ColoCare [OR per 1-standard deviation (SD) = 0.44; 95% CI, 0.31-0.64] and EPIC (OR per 1-SD = 0.86; 95% CI, 0.74-0.99). Comparing detectable versus non-detectable levels, serotonin was positively associated with colon cancer in CORSA (OR = 6.39; 95% CI, 3.61-11.3) and EPIC (OR = 2.03; 95% CI, 1.20-3.40). Kynurenine was inversely associated with colon cancer in ColoCare (OR per 1-SD = 0.74; 95% CI, 0.55-0.98), positively associated in CORSA (OR per 1-SD = 1.79; 95% CI, 1.27-2.52), while no association was observed in EPIC. The kynurenine-to-tryptophan ratio was positively associated with colon cancer in ColoCare (OR per 1-SD = 1.38; 95% CI, 1.03-1.84) and CORSA (OR per 1-SD = 1.44; 95% CI, 1.06-1.96), but not in EPIC. These results suggest that higher plasma tryptophan may be associated with lower colon cancer risk, while increased serotonin may be associated with a higher risk of colon cancer. The kynurenine-to-tryptophan ratio may also reflect altered tryptophan catabolism during colon cancer development. This article is protected by copyright. All rights reserved.
000169665 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000169665 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000169665 650_7 $$2Other$$aTryptophan
000169665 650_7 $$2Other$$acolon cancer
000169665 650_7 $$2Other$$akynurenine
000169665 650_7 $$2Other$$aplasma
000169665 650_7 $$2Other$$aserotonin
000169665 7001_ $$aGunter, Marc J$$b1
000169665 7001_ $$00000-0003-3347-8249$$aMurphy, Neil$$b2
000169665 7001_ $$aGicquiau, Audrey$$b3
000169665 7001_ $$aAchaintre, David$$b4
000169665 7001_ $$aBrezina, Stefanie$$b5
000169665 7001_ $$aGumpenberger, Tanja$$b6
000169665 7001_ $$aBaierl, Andreas$$b7
000169665 7001_ $$aOse, Jennifer$$b8
000169665 7001_ $$aGeijsen, Anne Jmr$$b9
000169665 7001_ $$avan Roekel, Eline H$$b10
000169665 7001_ $$00000-0002-9795-1528$$aGsur, Andrea$$b11
000169665 7001_ $$aGigic, Biljana$$b12
000169665 7001_ $$0P:(DE-HGF)0$$aHabermann, Nina$$b13
000169665 7001_ $$aUlrich, Cornelia M$$b14
000169665 7001_ $$aKampman, Ellen$$b15
000169665 7001_ $$aWeijenberg, Matty P$$b16
000169665 7001_ $$aUeland, Per-Magne$$b17
000169665 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b18$$udkfz
000169665 7001_ $$0P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aKatzke, Verena$$b19$$udkfz
000169665 7001_ $$00000-0003-0122-8624$$aKrogh, Vittorio$$b20
000169665 7001_ $$aBueno-de-Mesquita, Bas$$b21
000169665 7001_ $$aArdanaz, Eva$$b22
000169665 7001_ $$aTravis, Ruth C$$b23
000169665 7001_ $$aSchulze, Matthias B$$b24
000169665 7001_ $$aSánchez, Maria-José$$b25
000169665 7001_ $$aColorado-Yohar, Sandra M$$b26
000169665 7001_ $$00000-0003-2237-0128$$aWeiderpass, Elisabete$$b27
000169665 7001_ $$aScalbert, Augustin$$b28
000169665 7001_ $$00000-0001-9437-3040$$aKeski-Rahkonen, Pekka$$b29
000169665 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.33725$$gp. ijc.33725$$n9$$p1659-1669$$tInternational journal of cancer$$v149$$x1097-0215$$y2021
000169665 909CO $$ooai:inrepo02.dkfz.de:169665$$pVDB
000169665 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000169665 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b18$$kDKFZ
000169665 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aDeutsches Krebsforschungszentrum$$b19$$kDKFZ
000169665 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000169665 9130_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000169665 9141_ $$y2021
000169665 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2021-02-04$$wger
000169665 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2021-02-04$$wger
000169665 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-02-04
000169665 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-02-04
000169665 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-02-04
000169665 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2021-02-04
000169665 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-04
000169665 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-02-04
000169665 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-02-04
000169665 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-04
000169665 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-02-04
000169665 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2019$$d2021-02-04
000169665 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2019$$d2021-02-04
000169665 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x0
000169665 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x1
000169665 980__ $$ajournal
000169665 980__ $$aVDB
000169665 980__ $$aI:(DE-He78)C120-20160331
000169665 980__ $$aI:(DE-He78)C020-20160331
000169665 980__ $$aUNRESTRICTED